Macguire Cheswick & Tuttle Investment Counsel LLC lowered its stake in shares of Mylan N.V. (NASDAQ:MYL) by 7.9% during the second quarter, Holdings Channel reports. The firm owned 124,185 shares of the company’s stock after selling 10,700 shares during the period. Macguire Cheswick & Tuttle Investment Counsel LLC’s holdings in Mylan N.V. were worth $4,821,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Wellington Management Group LLP increased its position in shares of Mylan N.V. by 2.6% in the first quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company’s stock valued at $1,808,088,000 after buying an additional 1,165,852 shares in the last quarter. BlackRock Inc. increased its position in shares of Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after buying an additional 37,728,274 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Mylan N.V. by 3.9% in the first quarter. Vanguard Group Inc. now owns 29,348,816 shares of the company’s stock valued at $1,144,310,000 after buying an additional 1,090,791 shares in the last quarter. State Street Corp increased its position in shares of Mylan N.V. by 1.2% in the first quarter. State Street Corp now owns 20,176,564 shares of the company’s stock valued at $786,700,000 after buying an additional 234,521 shares in the last quarter. Finally, Pzena Investment Management LLC purchased a new position in shares of Mylan N.V. during the first quarter valued at about $283,158,000. Institutional investors and hedge funds own 70.19% of the company’s stock.

Shares of Mylan N.V. (NASDAQ MYL) opened at 30.88 on Friday. The company has a market capitalization of $16.56 billion, a P/E ratio of 24.96 and a beta of 1.27. The company’s 50 day moving average is $37.34 and its 200-day moving average is $39.01. Mylan N.V. has a 1-year low of $29.58 and a 1-year high of $49.42.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.18 by $0.08. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. During the same quarter in the previous year, the business posted $1.16 EPS. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. On average, equities research analysts forecast that Mylan N.V. will post $4.68 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/macguire-cheswick-tuttle-investment-counsel-llc-sells-10700-shares-of-mylan-n-v-nasdaqmyl/1478675.html.

Several equities analysts recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating for the company in a report on Thursday, May 11th. Wells Fargo & Company reissued a “market perform” rating and set a $40.00 price target on shares of Mylan N.V. in a report on Wednesday, May 31st. Zacks Investment Research raised shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, May 25th. BidaskClub raised shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Barclays PLC raised shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $47.00 to $50.00 in a report on Monday, May 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $47.83.

In other news, insider Anthony Mauro sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Rajiv Malik sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the sale, the president now directly owns 799,855 shares of the company’s stock, valued at approximately $31,994,200. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by company insiders.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.